| Name | Title | Contact Details |
|---|
Recruit Group is a global technology company transforming the world of work. We do so by simplifying hiring, helping businesses work smarter, and delivering sustainable growth while creating equitable social impact that enables everyone to prosper together. Operating in more than 60 countries, with key subsidiaries including Indeed, Glassdoor, and its worldwide staffing business, Recruit Group offers a two-sided talent marketplace that drives meaningful connections between job seekers and employers. In Japan, Recruit Group is also focused on streamlining business essentials from sourcing to marketing through its cloud-based smart solutions including matching platforms and SaaS. Founded in 1960 in Tokyo, Japan, Recruit Groups mission is to create opportunities for life. We are focused on continued innovation that better matches individuals and businesses around the world in a faster, simpler, and more human way.
Zoetis Petcare has been developing innovative health products for the pets you love for over 60 years.
Opinionlab Inc is a Highland Park, IL-based company in the Business Services sector.
Genesis Disc Jockey is a Attleboro, MA-based company in the Business Services sector.
We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)